These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 29279332)
21. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312 [TBL] [Abstract][Full Text] [Related]
22. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011 [TBL] [Abstract][Full Text] [Related]
23. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation. Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955 [TBL] [Abstract][Full Text] [Related]
25. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967 [TBL] [Abstract][Full Text] [Related]
28. HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM. Chang HY; Huynh M; Roopra A; Callander NS; Miyamoto S Blood Adv; 2023 Nov; 7(22):6859-6872. PubMed ID: 37647592 [TBL] [Abstract][Full Text] [Related]
29. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition. Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692 [TBL] [Abstract][Full Text] [Related]
30. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma. Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322 [TBL] [Abstract][Full Text] [Related]
31. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764 [TBL] [Abstract][Full Text] [Related]
32. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091 [TBL] [Abstract][Full Text] [Related]
33. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo. Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928 [TBL] [Abstract][Full Text] [Related]
34. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669 [TBL] [Abstract][Full Text] [Related]
35. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts. Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356 [TBL] [Abstract][Full Text] [Related]
36. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764 [TBL] [Abstract][Full Text] [Related]
37. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance. Meinel FG; Mandl-Weber S; Baumann P; Leban J; Schmidmaier R Mol Cancer Ther; 2010 Feb; 9(2):300-10. PubMed ID: 20124446 [TBL] [Abstract][Full Text] [Related]
38. Fibromodulin suppresses nuclear factor-kappaB activity by inducing the delayed degradation of IKBA via a JNK-dependent pathway coupled to fibroblast apoptosis. Lee YH; Schiemann WP J Biol Chem; 2011 Feb; 286(8):6414-22. PubMed ID: 21156791 [TBL] [Abstract][Full Text] [Related]
39. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656 [TBL] [Abstract][Full Text] [Related]